Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4551 - Patterns of progression under antiPD1/PDL1 in advanced NSCLC patients allow discriminating pseudo-progression from real progression.

Date

10 Sep 2017

Session

Poster display session

Topics

Cancers in Adolescents and Young Adults (AYA);  Immunotherapy;  Non-Small Cell Lung Cancer

Presenters

CAROLINE CARAMELLA

Citation

Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376

Authors

C. CARAMELLA1, M. Tazdait1, L. Mezquita2, J. Lahmar2, R. Ferrara2, A. Marabelle3, C. Balleyguier1, D. Planchard2, A. Gazzah4, J. Soria5, B. Besse2

Author affiliations

  • 1 Imaging, GUSTAVE ROUSSY, 94800 - Villejuif/FR
  • 2 Medical Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 3 Département D’innovation Thérapeutique Et D’essais Précoces, Gustave Roussy, Université Paris-Saclay, Villejuif/FR
  • 4 Départemement D’innovation Thérapeutique Et Des Essais Précoces (ditep), Institut Gustave Roussy, 94800 - Villejuif/FR
  • 5 Drug Development Department (ditep), Institut Gustave Roussy, 94800 - Villejuif/FR
More

Resources

Abstract 4551

Background

Immunotherapy (IT) is now a standard of care in advanced NSCLC patients. However, patients may present with various patterns of response, including initial progression followed by long stabilization or response, making it difficult to decide whether or not we should continue the treatment at the occurrence of progression. Our aim was to explore the patterns of responses based on CT-scans in order to differentiate real progression (PD) from pseudoprogression (PsPD).

Methods

We conducted a retrospective analysis of all NSCLC patients treated with IT in our Institution. All CT-scans were reviewed and the responses were assessed by RECIST 1.1 and iRECIST criteria. Seven different patterns of PD were considered based on the combination of target (T) and/or non-target (NT) and/or new lesions (NL). A confirmatory CT scan was performed at 4 weeks to discriminate real progression from PsPD. PsPD was defined as any decrease or stable disease for at least 6 months following an initial progression. Dissociated responses (DR) were defined as concomitant progressing and responding lesions for patients treated at least 6 months. Patterns of PD were correlated with overall survival (OS).

Results

Out of 202 patients treated by IT, 39 patients (19%) were excluded due to the absence of confirmatory CT. 87 patients (53%) had an initial PD, confirmed by a subsequent CT, or by death related to tumor progression. 14 patients (9%) experienced PsPD or DR. PsPD or DR patients had higher OS than PD patients (p = 

Conclusions

On the first occurrence of progression upon IT, a concomitant increase of T, NT and appearance of NL or appearance of extra-thoracic visceral lesions were strongly suggestive of real PD. IT should be stopped in these patients, and a confirmatory CT scan should be avoided.

Clinical trial identification

Legal entity responsible for the study

Gustave Roussy

Funding

None

Disclosure

A. Marabelle: Reports personal fees from Roche/Genentech, personal fees from Bristol-Myers Squibb, personal fees from Merck, personal fees from Pfizer, personal fees from AstraZeneca, outside the submitted work. D. Planchard: Reports consultancy for Boehringer Ingelheim, Lilly, MSD, Novartis, Chagai, Roche/Genentech, Bristol-Myers Squibb, Merck, Pfizer, AstraZeneca, outside the submitted work. J-C. Soria: Discloses consultanty fees from AstraZeneca, Astex, Clovis, GSK, Gammamabs, Lilly, MSD, Mission Therapeutics, Meurs, Pfizer, PharmaMar, Pierre Fabre, Roche, Sanofi, Servier, Symphogen, Takeda B. Besse: Discloses research grants from Bristol-Myers Squibb, MSD, Roche, Merck and AstraZeneca All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.